Search PubMed⌕ Search

Biomedical subjects

M Hanna

Publications and source records attributed to M Hanna.

At least 73 records · Page 4Linked to original sources
PubMed1989

Intravesical bacillus Calmette-Guérin and second primary malignancies.

In an effort to answer the question, "Does intravesical bacillus Calmette-Guérin (BCG) therapy increase the incidence of second primary malignancies," the records of 153 patients treated with BCG for carcinoma in situ of the urinary bladder were reviewed. The weight of the available evidence suggests that intravesical BCG does not increase the incidence of second primary malignancies. While this question should be investigated, at the present time it appears that the advantage of intravesical BCG for high-risk patients with superficial bladder cancer outweighs the known disadvantages.

BCG Vaccine↗
PubMed1989

BCG in the management of superficial bladder cancer.

An overall comparison of different types of therapy for any disease is difficult. A definition of the disease, which included carcinoma in situ was not agreed upon in 1961 when thiotepa was first described. Most importantly, many series are not prospective and randomized. Response criteria have varied and have not always included cytologies. With these shortcomings in mind we have attempted to compare the various therapeutic agents. The response rate for BCG appears superior to chemotherapy for the treatment of superficial bladder cancer (59% vs 45%), for prophylaxis (77% vs 53%) and the management of carcinoma in situ (74% vs 52%). Moreover BCG also appears superior to chemotherapy for the management of prior treatment failures, particularly carcinoma in situ. In summary, this review of the literature suggests that BCG is superior, in terms of response rate, to available chemotherapy in the management of superficial bladder cancer.

Administration, Intravesical↗
PubMed1988

Absorption of buccal morphine. A comparison with slow-release morphine sulphate.

The absorption of buccal morphine was compared with that of slow-release morphine sulphate in human volunteers. Morphine concentration was assayed by high pressure liquid chromatography in serum samples obtained at intervals up to 8 hours after administration of morphine 20 mg. Similar mean maximum concentrations were obtained by either route, but the mean time to maximum concentration was longer after buccal than after enteral administration.

Absorption↗
PubMed1987

Frictional changes in force values caused by saliva substitution.

The objective of this study was to determine the magnitude of frictional force changes between several sizes of stainless steel orthodontic wires (0.018 inch round, 0.020 inch round, and 0.018 X 0.025 inch rectangular) and an edgewise bracket (0.022 X 0.028 inch slot) when an artificial saliva medium was introduced. The wires were secured in the bracket slots with a 0.010 inch polyurethane ligatures. The force values in the saliva substitute medium were compared with those produced in a dry control and in glycerin. Clinically significant differences among the environmental conditions and among the wire sizes were found. The introduction of saliva substitute provides a significant reduction in force values.

Dental Stress Analysis↗
PubMed1987

Serum morphine concentrations after buccal and intramuscular morphine administration.

1. This study compared serum concentrations of morphine after administration of a buccal tablet (25mg) with those after intramuscular injection (10mg). 2. Buccal morphine was administered to eleven healthy volunteers and intramuscular morphine was given to five preoperative surgical patients. Serum morphine concentrations were assayed by high performance liquid chromatography (h.p.l.c.) in samples taken up to 8 h after drug administration. 3. Mean maximum morphine concentrations were eight times lower after buccal administration than after intramuscular injection and occurred at a mean of 4 h later. Individual morphine concentration-time profiles showed marked interindividual variability after administration of the buccal tablet, consistent with considerable variation in tablet persistence time on the buccal mucosa.

Administration, Buccal↗
PubMed1986

Nontransferrin-bound serum iron in thalassemia and sickle cell patients.

Nontransferrin-bound iron (NTBI) was separated from transferrin bound iron (TBI) by DEAE-Sephadex-CDS filtration. TBI is eluted with Tris-NaCl buffer, NTBI that is retained on the column is eluted with citric acid. NTBI was identified in serum from thalassemia and sickle cell patients. Normal serum contained less than 6% NTBI as compared with 15-18% in patient's sera. NTBI levels were decreased significantly after 8 hr chelation with deferoxamine (DFO).

Adult↗
PubMed1986

Non-transferrin-bound iron in long-term transfusion in children with congenital anemias.

Non-transferrin-bound iron (NTBI), a potentially toxic compound, is increased in the serum of patients with iron overload and fully saturated transferrin. We found markedly elevated NTBI levels in 16 children (including nine with sickle cell disease and five with beta-thalassemia) with iron overload secondary to prolonged transfusion therapy. During iron chelation with subcutaneous desferrioxamine infusion, NTBI levels decreased to normal, but became elevated within 2 to 4 hours after discontinuation of desferrioxamine. NTBI causes hepatic and cardiac toxicity in experimental systems, but our patients lacked sufficient organ dysfunction for this association to be made. The use of continuous 24-hour chelation to maintain NTBI at low levels may prevent progressive iron toxicity in patients who first received chelation therapy at an older age or who already have evidence of cardiac damage.

Adolescent↗
PubMed1986

Buccal morphine premedication. A double-blind comparison with intramuscular morphine.

Fifty patients were admitted to a double-blind, double-dummy study comparing buccal morphine 10 mg tablets and intramuscular morphine sulphate 13.5 mg as premedication. This investigation was performed on the basis of favourable results obtained in an earlier 25 patient pilot study designed to examine the efficacy, safety and patient acceptability of buccal morphine 10 mg tablets as pre-anaesthetic medication. Both studies and sets of results are presented and show that, whilst buccal morphine is a safe alternative means of delivering opioid premedication, which is acceptable to the majority of patients, an equivalent intramuscular morphine dose is nevertheless a more effective premedicant in terms of anxiolysis and wakefulness, as assessed by linear analogue scores. Pharmacokinetic considerations are advanced both to explain the differing clinical efficacies of the two means of morphine administration and to indicate that improved per- and immediate postoperative analgesia might be obtainable in patients premedicated with buccal morphine.

Administration, Oral↗
PubMed1984

Systemic herpes simplex virus type 2 infection. Proctitis, urinary retention, arthralgias, and meningitis in the absence of primary mucocutaneous lesions.

A 24-year-old heterosexual man had severe proctalgia associated with nonspecific proctitis. Within a few days, perineal and lower extremity paresthesias, intermittent urinary retention, inguinal lymphadenopathy, lower extremity arthralgias, and aseptic meningitis developed. Serologic studies demonstrated a fourfold rise in convalescent antibody titer to herpes simplex virus (HSV) consistent with an initial type 2 infection. Six months later, HSV type 2 was isolated from perianal vesicles, which we believe was the first cutaneous manifestation of a recurrence. This unusual syndrome, presumably the result of HSV ganglionitis, could be confused with other disorders that include multiple sclerosis, lumbar disk disease with radiculopathy, rheumatologic disease, and psychogenic illness. In the absence of typical herpetic mucocutaneous vesicles, serologic studies may be useful in the diagnosis of a systemic herpes simplex infection.

Adult↗
PubMed1983

Captopril.

Explore the source record for details and available documents.

Captopril↗